Experimental Therapeutics Program

Overview | Leaders | Research | Publications | Resources | Members

 

Scientific Accomplishments

A large number of scientific accomplishments from the Program have been published over recent years. These include the following, representative of all Specific Aims of the Program:

  • Identification of the structural determinants of the BRCA1 : estrogen receptor interaction (Ma et al., Oncogene, 2005)
  • Elucidating NK cell targets that promote antibody-dependent cellular cytotoxicity in a model of lymphoma (Binyamin et al., J Immunol, 2008)
  • Identification of transcription factor targets for the treatment of Ewing Sarcomas (Uren et al., Biochemistry, 2004)
  • Developing and completing preclinical testing of a novel tumor targeting delivery system to enhance the action of tubulin depolymerizing agents (Hwang et al., Mol Cancer Ther, 2008)
  • Production of small molecules for in vivo animal efficacy and toxicity studies of
    • Upregulating tumor suppressor proteins (RASSF1A)
    • Epigenetic targets such as Sert1 (activation) and selective HDAC isotypes
  • Preclinical studies were also completed for small molecules targeting
    • Voltage activated sodium channels
    • Class II HDACs
    • CDK isotypes
    • EWS/FLI1 (Erkizan et al., Nature Medicine, in press)
  • Phase I to Phase III development of CEA cancer vaccine (Marshall et al., JCO, 2005)
  • Development of raf anti-sense discovery to first in human clinical trial (Rudin et al., Clin Cancer Res, 2006)
  • First in human trial of novel AKT anti-sense RX-0201 (Malik et al., Proc ASCO, 2006)